Antihyperuricemic agents are also called anti-gout drugs. These drugs correct the overproduction or underexcretion of uric acid.
This report contains market size and forecasts of Antihyperuricemic Agents in global, including the following market information:
Global Antihyperuricemic Agents Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Antihyperuricemic Agents Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Antihyperuricemic Agents companies in 2021 (%)
The global Antihyperuricemic Agents market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Inhibit Uric Acid Production Agents Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Antihyperuricemic Agents include Takeda Pharmaceuticals, Hikma, Wockhardt, West Ward Pharmaceuticals, Rhea Pharmaceutical, Medinova, Odan Laboratories, TEIJIN and Casper Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antihyperuricemic Agents manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antihyperuricemic Agents Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Antihyperuricemic Agents Market Segment Percentages, by Type, 2021 (%)
Inhibit Uric Acid Production Agents
Promote Uric Acid Excretion Agents
Others
Global Antihyperuricemic Agents Market, by Distribution Channel, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Antihyperuricemic Agents Market Segment Percentages, by Distribution Channel, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Antihyperuricemic Agents Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Antihyperuricemic Agents Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Antihyperuricemic Agents revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Antihyperuricemic Agents revenues share in global market, 2021 (%)
Key companies Antihyperuricemic Agents sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Antihyperuricemic Agents sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Takeda Pharmaceuticals
Hikma
Wockhardt
West Ward Pharmaceuticals
Rhea Pharmaceutical
Medinova
Odan Laboratories
TEIJIN
Casper Pharma
Dr. Reddys Laboratories
Teva
Zydus Pharmaceuticals
Mylan
Sun Pharmaceutical
APOTEX
NorthStar Healthcare
Ipca Laboratories
Accord Healthcare
Gentec Pharmaceutical Group
Indoco Remedies
Lupin
Waterstone Pharmaceuticals
ALP Pharm
Jiangsu Hengrui Medicine
Jiangsu Wanbang Biopharmaceuticals
Hangzhou Zhuyangxin Pharmaceutical
YiChang HEC ChangJiang Pharmaceutical
KPC Pharmaceuticals
Tonghua Limin
Beijing Jialin Pharmaceutical